围术期输血对良性指征微创子宫切除术后并发症的影响
基于美国外科医师学会国家手术质量改进计划(ACS-NSQIP)2012至2016年数据,纳入90231例因良性指征行微创子宫切除术的患者,其中1447例(1.6%)接受围术期异体输血。多因素分析显示,围术期异体输血与感染性伤口事件(aOR 1.96)、血栓栓塞事件(aOR 2.75)和脓毒症事件(aOR 6.49)风险升高独立相关。
要点
- 围术期异体输血与感染性伤口事件风险升高独立相关(aOR 1.96,95%CI 1.9-2.58,p<.001)。
- 围术期异体输血与血栓栓塞事件风险升高独立相关(aOR 2.75,95%CI 1.5-5.05,p=.001)。
- 围术期异体输血与脓毒症事件风险升高独立相关(aOR 6.49,95%CI 4.29-9.79,p<.001)。
核心结论
- 围术期异体输血增加微创子宫切除术后并发症风险,妇科外科医生应考虑围术期贫血的替代治疗,包括静脉铁剂补充、红细胞生成刺激剂、等容血液稀释和术前激素抑制,以减少与围术期异体输血相关的并发症。
研究设计与样本
- 回顾性队列研究,数据来自参与美国外科医师学会国家手术质量改进计划(ACS-NSQIP)的医院,纳入2012至2016年间因良性指征行微创子宫切除术的患者90231例,排除同期开放子宫切除术、脱垂或恶性肿瘤者,围术期异体输血定义为术前、术中或术后接受红细胞输注。
主要发现
- 90231例符合纳入标准的患者中,1447例(1.6%)接受围术期输血。
- 多因素分析调整混杂因素后,围术期异体输血与感染性伤口事件独立相关(aOR 1.96,95%CI 1.9-2.58,p<.001)。
- 围术期异体输血与血栓栓塞事件独立相关(aOR 2.75,95%CI 1.5-5.05,p=.001)。
- 围术期异体输血与脓毒症事件独立相关(aOR 6.49,95%CI 4.29-9.79,p<.001)。
临床怎么用
- 作者建议妇科外科医生考虑围术期贫血的替代治疗,包括静脉铁剂补充、红细胞生成刺激剂、等容血液稀释和术前激素抑制,以减少与围术期异体输血相关的并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To examine the impact of perioperative allogeneic blood transfusion (ABT) on postoperative infectious wound occurrences, sepsis-related events. and venous thromboembolism. DESIGN: Retrospective cohort study. SETTING: Hospitals participating in the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). PATIENTS: Patients who underwent a minimally invasive hysterectomy for benign indications between 2012 and 2016 were selected from the ACS-NSQIP. Patients with concurrent open hysterectomy, prolapse, or malignancy were excluded. Those with preoperative, intraoperative or postoperative red blood cell transfusion were considered positive for perioperative ABT. INTERVENTION: Minimally invasive hysterectomy for benign indications. MEASUREMENTS AND MAIN RESULTS: Univariate analyses were performed to determine associations of preoperative and intraoperative patient variables and postoperative outcomes with perioperative ABT. Multivariate analysis was completed to test the independent associations of perioperative ABT with outcomes while adjusting for possible confounders. Of the 90,231 patients who met our inclusion criteria, 1447 had a perioperative transfusion (1.6%). Perioperative ABT was associated with multiple preoperative variables. After multivariate analysis, perioperative ABT remained significantly associated with infectious wound events (adjusted odds ratio [aOR], 1.96; 95% confidence interval [CI], 1.9-2.58; p < .001), thromboembolic events (aOR, 2.75; 95% CI, 1.5-5.05; p = .001), and sepsis events (aOR, 6.49; 95% CI, 4.29-9.79, p < .001). CONCLUSION: ABT is a commonly used to treat perioperative anemia in patients undergoing gynecologic surgery. The results of this study, however, show that perioperative ABT increases a patient's risk of postoperative complications following minimally invasive hysterectomy. Gynecologic surgeons should consider the use of alternative treatments for perioperative anemia, including intravenous iron supplementation, erythropoiesis-stimulating agents, normovolemic hemodilution, and preoperative hormonal suppression, to help reduce the morbidity associated with perioperative ABT.
引用
- Tyan P, Taher A, Carey E, et al. Effect of Perioperative Transfusion on Postoperative Morbidity Following Minimally Invasive Hysterectomy for Benign Indications. J Minim Invasive Gynecol. 2019. PMID: 30930213. doi:10.1016/j.jmig.2019.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。